539 related articles for article (PubMed ID: 29956427)
1. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
[TBL] [Abstract][Full Text] [Related]
2. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
3. Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
Alroughani R; Akhtar S; Ahmed S; Behbehani R; Al-Hashel J
PLoS One; 2016; 11(11):e0165846. PubMed ID: 27802328
[TBL] [Abstract][Full Text] [Related]
4. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.
Achiron A; Barak Y; Rotstein Z
Mult Scler; 2003 Oct; 9(5):486-91. PubMed ID: 14582775
[TBL] [Abstract][Full Text] [Related]
6. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
7. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
8. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.
Usta NC; Boz C; Terzi M
Clin Neurol Neurosurg; 2023 Jan; 224():107528. PubMed ID: 36446265
[TBL] [Abstract][Full Text] [Related]
9. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
Oreja-Guevara C; Charil A; Caputo D; Cavarretta R; Sormani MP; Filippi M
Arch Neurol; 2006 May; 63(5):736-40. PubMed ID: 16682543
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis.
Mirmosayyeb O; Brand S; Barzegar M; Afshari-Safavi A; Nehzat N; Shaygannejad V; Sadeghi Bahmani D
J Clin Med; 2020 May; 9(5):. PubMed ID: 32370288
[TBL] [Abstract][Full Text] [Related]
11. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up.
Strautmane S; Balodis A; Teivane A; Grabovska D; Naudins E; Urbanovics D; Fisermans E; Mednieks J; Flintere-Flinte A; Priede Z; Millers A; Zolovs M
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374286
[No Abstract] [Full Text] [Related]
12. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
[TBL] [Abstract][Full Text] [Related]
14. The impairment of the functional system and fatigue at the onset of the disease predict reaching disability milestones in relapsing-remitting multiple sclerosis differently in female and male patients.
Ivaniuk A; Solodovnikova Y; Marusich T; Son A
Acta Neurol Belg; 2021 Dec; 121(6):1699-1706. PubMed ID: 32997326
[TBL] [Abstract][Full Text] [Related]
15. Long-term disability progression of pediatric-onset multiple sclerosis.
McKay KA; Hillert J; Manouchehrinia A
Neurology; 2019 Jun; 92(24):e2764-e2773. PubMed ID: 31092624
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
[TBL] [Abstract][Full Text] [Related]
17. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
18. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
[TBL] [Abstract][Full Text] [Related]
19. Predicting the course of relapsing-remitting MS using longitudinal disability curves.
Achiron A
J Neurol; 2004 Sep; 251 Suppl 5():v65-v68. PubMed ID: 15549358
[TBL] [Abstract][Full Text] [Related]
20. First-line therapies in late-onset multiple sclerosis: An Italian registry study.
Zanghì A; Avolio C; Amato MP; Filippi M; Trojano M; Patti F; D'Amico E;
Eur J Neurol; 2021 Dec; 28(12):4117-4123. PubMed ID: 34216532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
